MX356028B - Compuesto adyuvante. - Google Patents

Compuesto adyuvante.

Info

Publication number
MX356028B
MX356028B MX2014004114A MX2014004114A MX356028B MX 356028 B MX356028 B MX 356028B MX 2014004114 A MX2014004114 A MX 2014004114A MX 2014004114 A MX2014004114 A MX 2014004114A MX 356028 B MX356028 B MX 356028B
Authority
MX
Mexico
Prior art keywords
compound
directed
composition
sulphur
adjuvant compound
Prior art date
Application number
MX2014004114A
Other languages
English (en)
Spanish (es)
Other versions
MX2014004114A (es
Inventor
Antonius Ossendorp Ferdinand
Johannes Maria Milief Cornelis
Viktorovitsj Filippov Dmitri
Arie Van Der Marel Gijsbert
Khan Selina
Original Assignee
Isa Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isa Pharmaceuticals B V filed Critical Isa Pharmaceuticals B V
Publication of MX2014004114A publication Critical patent/MX2014004114A/es
Publication of MX356028B publication Critical patent/MX356028B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
MX2014004114A 2011-10-05 2012-10-04 Compuesto adyuvante. MX356028B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161543510P 2011-10-05 2011-10-05
NL2007536A NL2007536C2 (en) 2011-10-05 2011-10-05 Adjuvant compound.
US201261615566P 2012-03-26 2012-03-26
PCT/NL2012/050694 WO2013051936A1 (en) 2011-10-05 2012-10-04 Adjuvant compound

Publications (2)

Publication Number Publication Date
MX2014004114A MX2014004114A (es) 2014-10-17
MX356028B true MX356028B (es) 2018-05-09

Family

ID=48043964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004114A MX356028B (es) 2011-10-05 2012-10-04 Compuesto adyuvante.

Country Status (16)

Country Link
US (2) US9314521B2 (2)
EP (1) EP2763697B9 (2)
JP (1) JP6099210B2 (2)
KR (1) KR102053699B1 (2)
CN (1) CN104244976B (2)
AU (1) AU2012319265B2 (2)
BR (1) BR112014008214B1 (2)
CA (1) CA2886631C (2)
EA (1) EA030741B1 (2)
ES (1) ES2952644T3 (2)
IL (1) IL231951B (2)
IN (1) IN2014DN03325A (2)
MX (1) MX356028B (2)
NL (1) NL2007536C2 (2)
SG (1) SG11201401291XA (2)
WO (1) WO2013051936A1 (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105102427B (zh) 2013-03-21 2018-09-07 赛诺菲-安万特德国有限公司 含有环状酰亚胺的肽产物的合成
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
EP3148566B1 (en) 2014-06-02 2024-04-03 ISA Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
MY196837A (en) 2015-12-11 2023-05-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
KR20180128915A (ko) 2016-02-26 2018-12-04 오클랜드 유니서비시즈 리미티드 아미노산 및 펩티드 접합체 및 접합 방법
MY201964A (en) 2016-06-20 2024-03-27 Isa Pharmaceuticals B V Formulation of a peptide vaccine
EP3484518B1 (en) 2016-07-07 2024-08-14 The Board of Trustees of the Leland Stanford Junior University Antibody adjuvant conjugates
US12370255B2 (en) 2017-04-04 2025-07-29 Barinthus Biotherapeutics North America, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
AU2020397499A1 (en) 2019-12-07 2022-06-16 Erasmus University Medical Center Rotterdam Treatment of diseases related to hepatitis B virus
EP4100051A2 (en) 2020-02-07 2022-12-14 ISA Pharmaceuticals B.V. Treatment of hpv-related diseases
WO2021214297A1 (en) 2020-04-23 2021-10-28 Isa Pharmaceuticals B.V. Immunization against sars-cov-related diseases
WO2023285412A1 (en) 2021-07-12 2023-01-19 Isa Pharmaceuticals B.V. Improved substance quantification in complex mixtures
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
AU2023361181A1 (en) 2022-10-13 2025-05-22 Isabella Pharma B.V. Modified long peptides suitable for use in immunisation
WO2024149888A1 (en) 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification
WO2025008085A1 (en) 2023-07-05 2025-01-09 Isa Pharmaceuticals B.V. Immunotherapy for the treatment of prame-expressing cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (de) * 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
DE3937412A1 (de) * 1989-11-10 1991-05-16 Hoechst Ag Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
AU769143B2 (en) 1999-06-30 2004-01-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
NL1012739C2 (nl) 1999-07-29 2001-01-30 Maasland Nv Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer.
CA2431500C (en) 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
MXNL04000056A (es) 2004-06-30 2006-01-11 Mario Alberto Aguilera Rico Sistema de construccion terra acero.
AU2007284656A1 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
AU2008230240B2 (en) 2007-03-26 2012-09-13 Academisch Ziekenhuis Leiden H.O.D.N. Lumc PRAME derived peptides and immunogenic compositions comprising these
AU2008257791B2 (en) 2007-05-31 2013-03-28 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
EP2152729B1 (en) 2007-05-31 2013-03-20 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
EP2549990A1 (en) * 2010-03-23 2013-01-30 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.

Also Published As

Publication number Publication date
EP2763697B1 (en) 2023-06-07
JP6099210B2 (ja) 2017-03-22
IL231951A0 (en) 2014-05-28
EA201490709A1 (ru) 2014-09-30
EP2763697B8 (en) 2023-07-12
EA030741B1 (ru) 2018-09-28
CN104244976B (zh) 2017-05-31
BR112014008214B1 (pt) 2022-07-05
MX2014004114A (es) 2014-10-17
EP2763697A1 (en) 2014-08-13
SG11201401291XA (en) 2014-05-29
CA2886631A1 (en) 2013-04-11
BR112014008214A2 (pt) 2017-06-13
KR20140093673A (ko) 2014-07-28
EP2763697C0 (en) 2023-06-07
JP2014530808A (ja) 2014-11-20
KR102053699B1 (ko) 2019-12-09
EP2763697B9 (en) 2023-10-04
ES2952644T3 (es) 2023-11-02
CA2886631C (en) 2019-06-11
WO2013051936A9 (en) 2013-09-12
WO2013051936A1 (en) 2013-04-11
US20150104473A1 (en) 2015-04-16
NZ623869A (en) 2015-11-27
AU2012319265A1 (en) 2014-05-22
US9314521B2 (en) 2016-04-19
CN104244976A (zh) 2014-12-24
IL231951B (en) 2019-08-29
US9770506B2 (en) 2017-09-26
AU2012319265B2 (en) 2016-10-13
NL2007536C2 (en) 2013-04-08
IN2014DN03325A (2) 2015-06-26
US20160250325A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
MX356028B (es) Compuesto adyuvante.
WO2016077464A8 (en) Amino acid derivatives and their uses
MY200083A (en) Cyclic dinucleotide compounds
BR112012007411A2 (pt) composto, processo para sua preparação e composição farmacêutica contendo o mesmo
TR201900128T4 (tr) Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller.
PH12012501918A1 (en) Process for preparation of dopo-derived compounds and compositions thereof
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
MX2012002502A (es) Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos.
PH12012502352A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
JO2910B1 (en) Organic compounds
MX2011007952A (es) Tricianoboratos novedosos.
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
MX2013000295A (es) Procedimiento de preparacion de un inhibidor especifico de la trombina.
MX352607B (es) Proceso para la preparacion de benzoxaboroles.
MY182716A (en) Method for controlling arthropod pest
PH12013500694A1 (en) Process for manufacturing dihydropteridinones and intermediates thereof
BR112014008934A2 (pt) composição, método de obtenção da composição e formulação fitossanitária que a compreende
WO2009137444A3 (en) Cure accelerators for anaerobic curable compositions
MY167638A (en) Treatment composition for textile goods
NZ704155A (en) Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
MX2013003387A (es) Proceso para preparacion de producto de reaccion de urea ciclica y de aldehido multifuncional.
AR077332A1 (es) Procesos para la alquilacion de pirazoles
BR112014000085A2 (pt) derivados de ácido carboxílico com um anel oxazolo[4,5-c]piridina
EA201390170A1 (ru) Составы

Legal Events

Date Code Title Description
FG Grant or registration